Oncoinvent ASA – New share capital registered

Oncoinvent ASA has registered a share capital increase following its 8 January 2026 EGM resolution to issue 75 new shares to Abakus Invest AS to facilitate a reverse share split; the new shares will be recorded in the CSD under ISIN NO 0013251173. After registration the company's share capital is NOK 223,920,600, divided into 447,841,200 shares with a nominal value of NOK 0.50 each. The company is a clinical‑stage biotech developing Radspherin®, with completed Phase 1/1‑2a trials and an ongoing randomized Phase 2 across the US, UK and Europe and reportedly encouraging early efficacy data with no serious toxicity observed to date. The announcement is primarily an administrative corporate‑action update that may alter share structure and liquidity but does not change operational or clinical development outlook.

Analysis

Market structure: The reverse share split registration is primarily a corporate housekeeping move that reduces float and mechanically elevates per‑share price; this benefits large insiders (Abakus Invest) and market makers by reducing penny‑stock stigma while increasing short‑squeeze potential. It does not change Oncoinvent’s clinical runway or radium‑224 supply economics, but it signals management wants to preserve listing status and optionality for a near‑term financing or M&A (watch a capital raise within 3–9 months).

Risk assessment: Primary tail risks are binary clinical/regulatory failure in the ongoing randomized Phase‑2 (high impact, low prob.), a contamination or isotope supply disruption, and a cash‑runway shortfall forcing >30% dilution; any of these could zero equity value within 6–18 months. Near term (days–weeks) expect headline-driven volatility from the split; medium term (3–12 months) the key catalysts are interim Phase‑2 signals, manufacturing scale updates, and any NOK equity raise.

Trade implications: For risk‑seeking allocations, size exposure to Oncoinvent (OSE:ONCO) as a binary biotech: recommended 1–2% portfolio long ahead of Phase‑2 readout with a hard 30% stop; if options exist, prefer defined‑risk bullish structures (buy 12‑month calls or stock + 6‑month 30% OTM put). To hedge, short a small‑cap biotech ETF (XBI or IBB) equal to 0.5–1% notional to reduce sector beta while keeping directional exposure to onco‑specific upside.

Contrarian angles: Markets likely under‑price insider accumulation and the operational value of a proprietary radium‑224 manufacturing capability—if Oncoinvent proves scalable, it becomes an acquisition target at a sizable premium (20–100% depending on readout). Conversely, the reduced float can make the stock whip‑sawed; if management files for financing at >20% dilution, downside will accelerate — set sell triggers and track insider transactions and clinical DSMB updates closely.

Key Decisions for Investors

• Establish a 1–2% long position in Oncoinvent (OSE:ONCO) over 1–4 weeks, scaling in 25% increments; set a 30% stop‑loss and a target exit on a positive Phase‑2 primary endpoint or a 50–100% price gain within 6–18 months.
• If liquid, buy 12‑month call options on ONCO (or equivalent OTC calls) sized to 0.5–1% portfolio risk; alternatively, buy the stock and simultaneously purchase a 6‑month 30% OTM put to cap downside while retaining upside to Phase‑2 readout.
• Short 0.5–1% notional of a small‑cap biotech ETF (XBI or IBB) as a hedge to reduce sector beta; unwind hedge if ONCO announces manufacturing scale or strategic partnering (within 3 months of such announcement).
• Monitor three triggers before adding size: (1) DSMB/interim safety readout (next 3–9 months), (2) any announced equity raise (do not add if dilution >20%), and (3) insider share movements — increase conviction if Abakus raises stake >5% or if strategic partner announced.